Mobile

A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DOSE-RANGING STUDY TO EVALUATE LEBRIKIZUMAB (MILR1444A) IN ADULT PATIENTS WITH ASTHMA WHO ARE NOT TAKING INHALED CORTICOSTEROIDS (MOLLY)

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-013267-19

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The main objectives of this study are as follows; - To evaluate the efficacy of different doses of lebrikizumab compared with placebo as measured by relative change in pre-bronchodilator FEV1. - To evaluate the safety and tolerability of different doses of lebrikizumab.

Critère d'inclusion

  • Asthma in adult patients not taking inhaled corticosteroids

Liens